GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (BUE:NVS) » Definitions » Cyclically Adjusted PS Ratio

Novartis AG (BUE:NVS) Cyclically Adjusted PS Ratio : 4.96 (As of Jun. 09, 2024)


View and export this data going back to . Start your Free Trial

What is Novartis AG Cyclically Adjusted PS Ratio?

As of today (2024-06-09), Novartis AG's current share price is ARS31040.00. Novartis AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ARS6,257.55. Novartis AG's Cyclically Adjusted PS Ratio for today is 4.96.

The historical rank and industry rank for Novartis AG's Cyclically Adjusted PS Ratio or its related term are showing as below:

BUE:NVS' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.81   Med: 3.7   Max: 4.53
Current: 4.53

During the past years, Novartis AG's highest Cyclically Adjusted PS Ratio was 4.53. The lowest was 2.81. And the median was 3.70.

BUE:NVS's Cyclically Adjusted PS Ratio is ranked worse than
79% of 743 companies
in the Drug Manufacturers industry
Industry Median: 2.05 vs BUE:NVS: 4.53

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Novartis AG's adjusted revenue per share data for the three months ended in Mar. 2024 was ARS9,932.977. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ARS6,257.55 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Novartis AG Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Novartis AG's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Cyclically Adjusted PS Ratio Chart

Novartis AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.28 3.98 3.84 3.88 4.09

Novartis AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.85 4.11 4.28 4.09 4.17

Competitive Comparison of Novartis AG's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Novartis AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novartis AG's Cyclically Adjusted PS Ratio falls into.



Novartis AG Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Novartis AG's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=31040.00/6257.55
=4.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Novartis AG's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=9932.977/107.3549*107.3549
=9,932.977

Current CPI (Mar. 2024) = 107.3549.

Novartis AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 91.733 101.517 97.009
201409 91.035 101.247 96.527
201412 92.913 100.704 99.050
201503 87.995 100.339 94.148
201506 95.618 100.464 102.177
201509 96.298 99.785 103.603
201512 136.960 99.386 147.941
201603 143.848 99.475 155.243
201606 147.646 100.088 158.366
201609 153.342 99.604 165.274
201612 166.948 99.380 180.346
201703 152.105 100.040 163.227
201706 173.621 100.285 185.861
201709 188.561 100.254 201.918
201712 104.144 100.213 111.566
201803 191.669 100.836 204.061
201806 247.763 101.435 262.223
201809 358.420 101.246 380.048
201812 383.235 100.906 407.728
201903 382.878 101.571 404.682
201906 460.540 102.044 484.509
201909 607.809 101.396 643.531
201912 658.935 101.063 699.957
202003 688.287 101.048 731.250
202006 690.662 100.743 735.990
202009 808.706 100.585 863.140
202012 928.530 100.241 994.429
202103 1,009.691 100.800 1,075.352
202106 1,115.448 101.352 1,181.513
202109 1,159.738 101.533 1,226.243
202112 413.356 101.776 436.016
202203 1,230.099 103.205 1,279.562
202206 1,424.259 104.783 1,459.220
202209 1,374.585 104.835 1,407.628
202212 1,703.846 104.666 1,747.615
202303 2,058.807 106.245 2,080.320
202306 3,192.974 106.576 3,216.325
202309 4,078.646 106.570 4,108.705
202312 4,099.456 106.461 4,133.869
202403 9,932.977 107.355 9,932.977

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novartis AG  (BUE:NVS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Novartis AG Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Novartis AG's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Novartis AG (BUE:NVS) Business Description

Industry
Address
Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.